Obstetric and Perinatal Outcomes of Women With COVID-19

Obstetric and Perinatal Outcomes of Women With COVID-19: A Prospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04369859

Acronym

GROCO

Enrollment

556

Registered

2020-04-30

Start date

2020-04-23

Completion date

2022-01-15

Last updated

2022-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant Women

Brief summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently spreading rapidly around the globe, causing a major public health issue. There is currently very few data about the impact of COVID-19 on pregnancy, and potential in utero infection. This is a prospective observational study of COVID-19 diagnosed pregnant patients. This objective is to examine the impact of COVID-19 during pregnancy on the rates of obstetric and perinatal complications.

Detailed description

Clinical manifestations of COVID-19 can range from a benign upper respiratory tract infection to severe acute respiratory distress syndrome (ARDS), fatal in 1% of cases. However, pregnant women and their fetuses could particularly be vulnerable to the infection, as shown by previous human coronavirus outbreaks (SARS-CoV and MERS-CoV). Cases will be recruited among all pregnant women aged \>18 years old who have tested positive for COVID-19 and are followed in a maternity belonging to the French South Regional Perinatology Network. Voluntary physicians will refer eligible participants to the study-coordinating center at APHM University Hospital. The participants will be followed by phone after having provided an informed consent. Clinical symptoms, laboratory and imaging findings, maternal and perinatal outcomes will be recorded.

Interventions

BEHAVIORALExamine the impact of COVID-19 during pregnancy

clinical data collection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pregnant women * Able to give informed consent * Diagnosed with COVID-19

Exclusion criteria

* Patients Refusing to Participate in the Study * Patients who do not speak French well enough to benefit from clear and intelligible information

Design outcomes

Primary

Measure	Time frame	Description
Compare the complications rates	12 months	To compare the complications rates of pregnant women tested positive for the SARS-CoV-2 (study group), with reference rates in a Covid-free population.

Secondary

Measure	Time frame	Description
Clinical presentation	12 months	To record clinical presentation of pregnant participants with COVID-19 by questionnaire and clinical evaluation

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026